Pre-Cure utilizes a multifunctional tumor-on-a-chip platform to enhance the precision of cancer treatment selection by simulating tumor responses in a controlled environment. This technology enables biopharma companies and healthcare providers to tailor therapies based on individual tumor characteristics, improving treatment efficacy and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Selecting effective cancer treatments is challenging due to the variability in tumor response to different therapies. Traditional methods lack the ability to accurately predict individual patient outcomes, leading to suboptimal treatment choices and potentially adverse effects.
Solution
Pre-Cure offers a tumor-on-a-chip platform that simulates tumor behavior in a controlled, three-dimensional microenvironment. This technology allows biopharmaceutical companies and healthcare providers to assess the efficacy of various cancer treatments on a patient's specific tumor cells before clinical application. By replicating the tumor microenvironment, the platform provides insights into drug responses, enabling personalized treatment strategies. The platform aims to improve treatment precision, reduce ineffective therapies, and enhance patient outcomes by tailoring interventions based on individual tumor characteristics.
Target Audience
The primary customers are biopharmaceutical companies seeking to optimize drug development and healthcare providers aiming to personalize cancer treatment strategies.
Features
- Multifunctional tumor-on-a-chip platform for simulating tumor responses
- Three-dimensional cell culture to mimic the in vivo tumor microenvironment
- Capability to test multiple drug candidates simultaneously
- Personalized treatment selection based on individual tumor characteristics